This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

About CIBINQOEfficacyEfficacyOverviewEfficacy of CIBINQO + Medicated TopicalsEfficacy of CIBINQO Without Medicated TopicalsReduction in Risk of FlaresLong-term Efficacy ResultsBefore and After PhotosGlossarySafetySafetySafety ProfileSafety ConsiderationsLab AbnormalitiesDosing & MonitoringDosing &
MonitoringDosingLab Monitoring

Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Skin clearance you can see1,2

Images of patients with moderate-to-severe AD from clinical trials. Not everyone will respond to treatment with CIBINQO. Individual results may vary.

Head

Trunk

Upper Extremities

Lower Extremities

FaceResults seen by week 2 and sustained through week 16, with CIBINQO + TCS
SEX: Male CLINICAL TRIAL: JADE COMPARE
AGE: 21 IGA AT BASELINE: Severe
DOSAGE: 200 mg QD IGA AT WEEK 2: Moderate
USE OF MEDICATED TOPICALS: Yes IGA AT WEEK 12: Clear
  IGA AT WEEK 16: Clear
TCS includes low- to medium-potency topical corticosteroids and other medicated topicals.2AD=atopic dermatitis; QD=once a day; IGA=Investigator's Global Assessment.Explore more About CIBINQO About CIBINQOLoading Safety Across Clinical Trials

Consistent safety profiles in patients with moderate-to-severe AD studied across JADE clinical trials

 See Safety Profile Loading

Prescribing information

Please see the CIBINQO Summary of Product Characteristics for more information.

References:Data on file. Pfizer Inc.; New York, NY.Bieber T, Simpson EL, Silverberg JI, et al; for the JADE COMPARE Investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101-1112.Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255-266.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Anterior TorsoResults seen by week 12, without TCS
SEX: Male CLINICAL TRIAL: JADE MONO-2
AGE: 48 IGA AT BASELINE: Moderate
DOSAGE: 200 mg QD IGA AT WEEK 12: Mild
USE OF MEDICATED TOPICALS: No
Patients in JADE MONO-1 and MONO-2 did not receive topical corticosteroids, topical calcineurin inhibitors, or topical phosphodiesterase-4 inhibitor, and rescue treatment was not permitted during the trials.2,3
TCS=topical corticosteroids; AD=atopic dermatitis; QD=once a day; IGA=Investigator’s Global Assessment.Explore moreAbout CIBINQO About CIBINQOLoading Safety Across Clinical Trials

Consistent safety profiles in patients with moderate-to-severe AD studied across JADE clinical trials

 See Safety Profile Loading

Prescribing information

Please see the CIBINQO Summary of Product Characteristics for more information.

References:Data on file. Pfizer Inc.; New York, NY.Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255-266.Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863-873.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Results seen by week 12, without TCSUpper Arms
SEX: Male CLINICAL TRIAL: JADE MONO-2
AGE: 45 IGA AT BASELINE: Severe
DOSAGE: 100 mg QD IGA AT WEEK 12: Mild
USE OF MEDICATED TOPICALS: No
Patients in JADE MONO-1 and MONO-2 did not receive topical corticosteroids, topical calcineurin inhibitors, or topical phosphodiesterase-4 inhibitor, and rescue treatment was not permitted during the trials.2,3
TCS=topical corticosteroids; AD=atopic dermatitis; QD=once a day; IGA=Investigator’s Global Assessment.Explore more About CIBINQO About CIBINQO  Loading Safety Across Clinical Trials

Consistent safety profiles in patients with moderate-to-severe AD studied across JADE clinical trials

 See Safety Profile Loading

Prescribing information

Please see the CIBINQO Summary of Product Characteristics for more information.

References:Data on file. Pfizer Inc.; New York, NY.Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255-266.Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863-873.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

LegsResults seen by week 12, without TCS
SEX: Female CLINICAL TRIAL: JADE MONO-2
AGE: 43 IGA AT BASELINE: Severe
DOSAGE: 200 mg QD IGA AT WEEK 12: Moderate
USE OF MEDICATED TOPICALS: No
Patients in JADE MONO-1 and MONO-2 did not receive topical corticosteroids, topical calcineurin inhibitors, or topical phosphodiesterase-4 inhibitor, and rescue treatment was not permitted during the trials.2,3
TCS=topical corticosteroids; AD=atopic dermatitis; QD=once a day; IGA=Investigator's Global Assessment.Explore moreAbout CIBINQOAbout CIBINQO Loading Safety Find out moreLoading

Prescribing information

Please see the CIBINQO Summary of Product Characteristics for more information.

References:Data on file. Pfizer Inc.; New York, NY.Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255-266.Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863-873.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Efficacy
Take On Moderate-to-Severe AD With CIBINQO

Discover the efficacy of CIBINQO

 See Efficacy OverviewLoading

Legal Category: S1A
Further information is available upon request

PP-CIB-IRL-0087 June 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.